Travere Therapeutics, Inc.
TVTX
株式のランク
#3418
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
株価
$52.95
最終同期: 2026-10-21
時価総額
$4.99B
変化（1日）
1.24%
変化（1年）
92.69%
国
US
取引 Travere Therapeutics, Inc. (TVTX)
カテゴリー
Healthcare
Travere Therapeutics, Inc.（TVTX）の株価履歴
終値の最高値: $53.35 （2026-10-01）
終値の最安値: $1.88 （2012-11-01）
終値の最安値: $1.88 （2012-11-01）
Travere Therapeutics, Inc. の株価履歴（2012 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 21.63% |
| 2025 | 98.56% |
| 2024 | 113.02% |
| 2023 | -57.16% |
| 2022 | -32.13% |
| 2021 | 10.99% |
| 2020 | 87.35% |
| 2019 | -40.02% |
| 2018 | 7.59% |
| 2017 | 9.33% |
| 2016 | -3.75% |
| 2015 | 81.19% |
| 2014 | 54.72% |
| 2013 | 74.64% |
| 2012 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
